Document is current
Any future updates will be listed below
-
Authors
Neueder, Andreas
Kojer, Kerstin
Hering, Tanja
Lavery, Daniel J.
Chen, Jian
Birth, Nathalie
Hallitsch, Jaqueline
Trautmann, Sonja
Parker, Jennifer
Flower, Michael
Sethi, Huma
Haider, Salman
Lee, Jong-Min
Tabrizi, Sarah J.
Orth, Michael http://orcid.org/0000-0002-6913-3536
-
Funding
Funding for this research was provided by:
CHDI Foundation (A-5497, A-5497)
Ministerium für Wissenschaft, Forschung und Kunst Baden-Württemberg (BioDATEN)
Deutsche Huntington Hilfe (n.a.)
Deutsche Forschungsgemeinschaft (NE 2372/1-1)
UK Dementia Research Institute (n.a.)
Medical Research Council (n.a.)
Alzheimer's Society and Alzheimer's Research (n.a.)
Wellcome Trust (200181/Z/15/Z)
National Institutes of Health (NS091161, NS105709, NS119471)
- License Information
-
More Information
Article History
Received: 14 February 2022
Accepted: 18 August 2022
First Online: 7 September 2022
Change Date: 14 January 2023
Change Type: Update
Change Details: Missing Open Access funding information has been added in the Funding Note.
Declarations
:
: The local ethics committees at Ulm University and University College London approved the study (Ulm: 265-12; London: 12/LO/1565), and written informed consent was obtained from each participant. All experimental methods comply with the Helsinki Declaration.
: Not applicable.
: J.M.L serves in the scientific advisory board of GenEdit, Inc. A.N. acts as a consultant for Triplet Therapeutics, Inc. In the past 2 years, through the offices of UCL Consultants Ltd, a wholly owned subsidiary of University College London, S.J.T. has undertaken consultancy services for Alnylam Pharmaceuticals Inc., Atalanta Pharmaceuticals, F. Hoffmann-La Roche Ltd, Genentech, Guidepoint, Horama, Locanobio, LoQus23 Therapeutics Ltd, Novartis Pharma, PTC Therapeutics, Sanofi, Spark Therapeutics, Takeda Pharmaceuticals Ltd, Triplet Therapeutics, University College Irvine and Vertex Pharmaceuticals Incorporated. All other authors declare no competing interests.
